Contact Info
Rafael Gabriel

He is a Professor of Public Health at the  National School of Public Health, Instituto Nacional de Salud Carlos III, formerly Head of Clinical Epidemiology Unit, Instituto IdiPAZ, Hospital Universitario La Paz, and Instituto IIS- Princesa, Madrid, Spain. He is a Member of the Executive Board of RIC (Red Española de Investigación Cardiovascular) and also the Coordinator of IBERCARMEN (Red Iberoamericana de Investigación en Prevención de Enfermedades Cardiometabólicas). He was visiting professor at the National Institute of Public Health in Mexico) and the Scientific Director of the Diabetes Foundation in Spain until 2009.


Graduated in 1980 in University of Salamanca, he specialized in internal medicine in Universidad Complutense, Madrid in 1985 and epidemiology in University of Texas, Houston in 1989. Since then his work as epidemiologist focused especially in the fields of Epidemiology and prevention of diabetes and cardiovascular diseases and aging,  participating in major International research projects on cardio-metabolic diseases, among them: ePREDICE: Early Prevention of Diabetes Complications in people with hyperglycaemia in Europe, MOSAIC: Models and Simulation Techniques for Discovering Diabetes Influences Factors, VIVA Study: Spanish Insulin Resistant Study Group-Metabolomic markers for the Progression to Diabetes, IBERCARMEN: Latin-American Network on Prevention of Cardiometabolic Diseases. IMAGE: Development and Implementation of a European Guidelines on “Diabetes Prevention” and of a curriculum for prevention managers, RISC: Relationships between Insulin Sensitivity and Cardiovascular Disease Risk, DREAM Trial: Diabetes Reduction with Ramipril and Rosiglitazone Medication. A Randomized Placebo-Controlled Trial. McMaster University (Canada), Glaxo Smith Kline & Sanofi-Aventis. He has authored more than 200 peer-reviewed original research publications.